您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Tranexamic Acid
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Tranexamic Acid
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Tranexamic Acid图片
CAS NO:1197-18-8
包装与价格:
包装价格(元)
10mM (in 1mL H2O)电议
5g电议
10g电议

产品介绍

化学性质

Physical AppearanceA solid
StorageStore at -20°C
M.Wt157.21
Cas No.1197-18-8
FormulaC8H15NO2
Solubilityinsoluble in EtOH; insoluble in DMSO; ≥6.6 mg/mL in H2O
Chemical Name4-(aminomethyl)cyclohexane-1-carboxylic acid
Canonical SMILESC1CC(CCC1CN)C(=O)O
运输条件蓝冰运输或根据您的需求运输。
一般建议为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。

资料参考

Tranexamic Acid is an antifibrinolytic, blocking lysine-binding sites (LBS) of plasmin and elastase-derived plasminogen fragments, with IC50 value of 5 mM [1].

Plasmin, generated from plasminogen under a reaction catalyzed by urokinase and tissue plasminogen activator, has a well-defined role in fibrinolysis. The LBS on plasmin and plasminogen mediate binding to fibrin and to cell surfaces, thereby enhancing the activation rate of plasminogen [1].

At concentrations of 0, 1, 2, 4, 6, 8, 10 μM, Tranexamic Acid dose-dependently inhibited porcine plasmin-induced neutrophil adherence to endothelial cell monolayers, with IC50 value of 5 mM. The neutrophil adherence inducing effect of plasmin was abolished under the treatment of 10 mM Tranexamic Acid [1].

In a rat bleeding model, where 8 mg/kg/h tissue plasmin activator (tPA) was continuously infused to prolong bleeding time beyond control values, Tranexamic Acid was administered by continuous infusion of 30, 100 mg/kg/h up to a dose of 300 mg/kg/h. Tranexamic Acid at 30 mg/kg/h showed no effects on bleeding, but exhibited a significant reduction in the bleeding time at 100 mg/kg/h, with the greatest effect seen at the highest dose of 300 mg/kg/h [2].

References:

[1]. Lo S K, Ryan T J, Gilboa N, et al. Role of catalytic and lysine-binding sites in plasmin-induced neutrophil adherence to endothelium. Journal of Clinical Investigation, 1989, 84(3): 793-801.

[2]. Sperzel M, Huetter J. Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation. Journal of Thrombosis and Haemostasis, 2007, 5(10): 2113-2118.